ArticleThe New England journal of medicine2023
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
Article in The New England journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.The Journal of infectious diseases · 2023Trial
- Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Nonhuman primate antigenic cartography of SARS-CoV-2.Cell reports · 2025Article
- Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.Journal of virology · 2024Article
- Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.Journal of virology · 2024Article
- Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Three immunizations with Novavax's protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.NPJ vaccines · 2024Article
- The Matrix-M™ adjuvant: A critical component of vaccines for the 21Human vaccines & immunotherapeutics · 2023Review
Corrections and comments
- AssociatedPublication
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.